MedTrace Logo

PrEP at a Syringe Services Program

NCT04782180 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-12-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.

Conditions

Interventions

DRUG

Descovy 200Mg 25Mg Tablet

daily Descovy tab by mouth

BEHAVIORAL

PrEP

PrEP will be provided in a community setting by community-based harm reduction program.

Sponsors & Collaborators

Principal Investigators

  • Hansel Tookes · University of Miami

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2024-11-11
Completion
2024-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04782180 on ClinicalTrials.gov